1st Quarter - Amendment

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2020 $50,000 Replaced
1st Quarter - Amendment (this page) Jul 8, 2020 $50,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
MARC LAMPKIN —
BRIAN MCKEON —
RADHA MOHAN —
JEROME MURRAY —
ZACHARY PFISTER —
BRIAN WILD —

Contacted: Office of the Vice President of the United States; SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 748 (116th)

Medical/Disease Research/Clinical Labs MED

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment

LobbyistCovered position, as disclosed
EMILY FELDER —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States

Bills named: H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.